- Marketwired•14 days ago
Critical Outcome Technologies Inc. a clinical-stage biopharmaceutical company advancing innovative and targeted therapies for the treatment of cancer, announced today that it has appointed...
- Marketwired•last month
Critical Outcome Technologies Inc. a clinical-stage biopharmaceutical company advancing innovative and targeted therapies for the treatment of cancer, announced the official opening of its...
- Zacks Small Cap Research•last month
The higher R&D expenses for the quarter were primarily due to the addition of clinical trial expenses, whereas there was no comparable expense in the same quarter of FYE 2015. The addition of clinical trial expenses was partially offset by a reduction in synthesis and miscellaneous R&D expenses with much of this reduction related to consulting fees incurred in writing and conducting additional tests in support of the IND submission to the FDA which occurred late in the fourth quarter of FYE 2015. The Company (COT.V) reported a quarterly net loss of $2.4 million ($0.02 per share) for fiscal 4Q16, compared to a net loss of $0.95 million ($0.01 per share) for the fourth quarter of the previous year.
Critical Outcome Technologies Inc. (COT.V)
TSXV - TSXV Delayed Price. Currency in CAD
|Day's Range||0.60 - 0.60|
|52wk Range||0.20 - 0.90|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-15.38|
|Avg Vol (3m)||98,822|
|Dividend & Yield||N/A (N/A)|